Gastric Cancer Drugs Global Market Report 2024

The gastric cancer drugs market size has grown rapidly in recent years. It will grow from $3.91 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth observed in the historical period can be ascribed to the rise in pharmaceutical research and development (R&D) expenditure, augmented healthcare spending, robust economic growth in emerging markets, and the swift expansion of the elderly population.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be ascribed to the increase in the incidence rate of gastric cancer, a robust pipeline of drugs, a surge in acquisitions and partnerships for drug development, a rise in healthcare expenditure, high potential in emerging economies, a growing geriatric population, and revised FDA regulations aimed at facilitating biologics drug development. Major trends expected in the forecast period include strategic collaborations and agreements to expand product portfolios, partnerships with other companies or government bodies to expedite the development of new drugs, an increase in the number of pipeline studies for the development of gastric cancer drugs, investments in AI solutions to reduce R&D costs, the development of next-generation biologics to enhance revenue and market share, and the use of CRISPR-Cas9 technology in new drug developments or for improved results in gastric cancer treatments.

The rising prevalence of obesity and an increasing number of smokers have contributed to a higher incidence of gastric cancer. Tobacco consumption and an unhealthy diet are identified as risk factors for stomach cancer. According to the American Institute for Cancer Research's 2020 estimates, approximately 27,600 cases of stomach cancer were projected to be diagnosed, with 16,980 in men and 10,620 in women. The growing number of gastric cancer cases is expected to fuel the expansion of the gastric cancer drugs market.

The expanding global aging population is anticipated to drive the future growth of the gastric cancer drug market. An aging population is characterized by a significant proportion of individuals aged 65 and above, resulting from increased life expectancy and reduced birth rates. This demographic shift necessitates tailored treatment options, including drugs, to accommodate the specific needs and tolerances of elderly patients who may have limited tolerance for certain cancer treatments such as surgery or chemotherapy. For example, as reported by The Print in August 2021, India's elderly population (aged 60 and above) is expected to reach 194 million by 2031, reflecting a 41% increase from 138 million in 2021, according to the National Statistical Office's Elderly in India 2021. Consequently, the gastric cancer drug market is poised for growth due to the expanding elderly population.

Numerous companies are employing combination therapies as a strategy to combat gastric cancer effectively. Combination therapies involve the simultaneous use of two or more drugs to treat a single disease, enhancing patient care. For instance, in January 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, announced the FDA approval of Enhertu (trastuzumab deruxtecan) in the US for treating adult patients with locally progressed or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. This therapy, combining trastuzumab with a fluoropyrimidine- and platinum-based chemotherapy, is administered to individuals facing advanced gastric cancer or GEJ adenocarcinoma who have previously undergone a trastuzumab-based regimen.

Major companies in the gastric cancer drugs market are introducing innovative medications such as Nivolumab (Opdivo) to maintain a competitive edge. Nivolumab is an immune checkpoint inhibitor belonging to the Programd death receptor-1 (PD-1) blockers class, used in cancer therapy. The incorporation of immune checkpoint inhibitors in gastric cancer treatment aligns with the broader effort to develop more targeted and effective therapies for the disease. For example, in April 2021, Bristol-Myers Squibb Company, a US-based biopharmaceutical company, received FDA approval for Opdivo (nivolumab) injection for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, irrespective of PD-L1 expression status.

In March 2021, Amgen Inc., a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics, Inc. for $1.9 billion. This strategic move by Amgen enhances its oncology product portfolio, assets for gastric cancer treatment, monoclonal antibody manufacturing capabilities, and drug development capabilities, particularly for biological drugs targeting advanced gastric or gastroesophageal junction (GEJ) cancer. Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology protein therapeutics for cancer treatment.

Major companies operating in the gastric cancer drugs market report are F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, GSK, Gilead Sciences, BMS, Ascedis Health.

North America was the largest region in the gastric cancer drugs market in 2023. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary types of gastric cancer drugs include doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. Sunitinib functions as both a chemotherapeutic agent and a receptor tyrosine kinase inhibitor, employed in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). These drugs are administered via oral and parenteral routes and find application in hospitals, clinics, and other healthcare settings.

The gastric cancer drugs market research report is one of a series of new reports that provides gastric cancer drugs market statistics, including gastric cancer drugs industry global market size, regional shares, competitors with a gastric cancer drugs market share, detailed gastric cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer drugs industry. This gastric cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer drugs market consists of sales of cyramza, docetaxel, and doxorubicin hydrochloride. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.